B CELL LYMPHOMA

This is a first-in-human study testing the safety and early effectiveness of a new, single-infusion CAR-T cell therapy called SynKIR-310. It is for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments, including other CAR-T …

This study is testing whether adding a new drug called sonrotoclax to an existing drug (zanubrutinib) works better for adults with mantle cell lymphoma that has returned or not responded to prior treatments. It will compare the two-drug combination against zanubrutinib plus a pla…

This study is testing whether combining an existing immunotherapy drug (pembrolizumab) with a vitamin A-based drug (ATRA) can help control lymphoma that has come back or stopped responding to standard treatments. It will enroll 24 adults with specific types of Hodgkin or B-cell n…

This is a first-in-human study testing a new personalized cell therapy called CLIC-2201 for adults and children with B-cell blood cancers that have returned or not responded to other treatments. The therapy involves collecting a patient's own immune cells, genetically modifying t…

This study is testing whether a new drug called BGB-16673 works better and is safe when combined with other cancer medicines for people with B-cell cancers that have returned or not responded to previous treatments. It will enroll about 80 adults whose cancer has come back or res…

This early-stage study is testing a new oral medication called LP-168 in adults whose B-cell lymphoma has returned or not responded to standard treatments. The main goals are to find a safe dose and see how the body processes the drug. Researchers will also look for early signs t…

This early-phase study is testing a new version of CAR-T cell therapy called U01 (ssCART-19) in adults and children (ages 2-75) with B-cell lymphoma that has returned or not responded to standard treatments. Doctors will collect a patient's own immune cells, modify them in a lab …

This early-stage trial is testing a new experimental drug called IKS03 in adults with advanced B-cell non-Hodgkin lymphomas that have returned or stopped responding to standard treatments. The study aims to find the safest and most effective dose by first testing increasing amoun…

This study is testing a combination of two immunotherapy drugs for people with a type of blood cancer called large B-cell lymphoma that has returned or didn't respond to first treatment. The goal is to see if using a personalized cell therapy (axi-cel) together with a targeted an…

This study is testing a new type of cell therapy called CTX112 for people with B-cell blood cancers that have come back or not responded to other treatments. Doctors use CRISPR gene-editing technology to modify donor immune cells to better target and fight the cancer. The main go…

This study is testing whether combining two drugs—mosunetuzumab and lenalidomide—works better than current treatments for people newly diagnosed with certain slow-growing lymphomas. The trial will enroll 52 adults who haven't had any previous cancer treatment. Doctors will adjust…

This study is testing a new cell therapy for patients whose blood cancers have returned or not responded to standard treatments. Researchers are giving patients specially engineered immune cells, called NK cells, which come from donated cord blood. The goal is to see if these mod…

This study is testing a combination of existing drugs to treat a dangerous immune system overreaction called HLH in people with B-cell lymphoma. The goal is to control this severe complication and improve survival. About 40 patients will receive the drug combination for 4 weeks, …

This early study is testing a new treatment called LCAR02, a gene injection designed to target CD19 on cancer cells, in up to 18 adults with B-cell lymphoma that has come back or not responded to standard treatments. The main goals are to check the safety of the treatment and see…

This study is testing a new type of CAR-T cell therapy for adults with a specific, difficult-to-treat form of B-cell lymphoma. The cancer in these patients does not have the CD19 marker, making it unresponsive to many existing CAR-T treatments. The main goal of this early-phase t…

This study is testing whether a combination of four different immunotherapy and targeted therapy drugs can help control two types of B-cell lymphoma that have returned after prior treatment. It will enroll about 36 adults whose lymphoma has progressed despite at least one previou…

This study is testing whether combining two existing drugs—rituximab and zanubrutinib—is safe and effective for people with untreated slow-growing B-cell lymphomas. It will enroll 43 adults with either follicular lymphoma or marginal zone lymphoma who need systemic treatment. Res…

This study aims to monitor the long-term safety of the drug pirtobrutinib in people with previously treated blood cancers like chronic lymphocytic leukemia and lymphoma. It is only open to a small group of 13 people who are already benefiting from the drug in a previous trial. Pa…

This study is testing a new, experimental CAR-T cell therapy designed to fight two targets (CD19 and CD22) on cancer cells at once. It is for children and young adults (ages 3-39) whose B-cell leukemia or lymphoma has come back or hasn't responded to standard treatments. Doctors …

This early-phase study is testing a new type of cell therapy called universal CAR-T (UWD-CD19) for people with B-cell cancers like lymphoma or leukemia that have come back or not responded to standard treatments. The goal is to see if this 'off-the-shelf' therapy, made from donor…

This study is testing if adding early palliative (comfort) care to standard cancer treatment improves well-being for patients with multiple myeloma or aggressive lymphoma. It will involve 144 patients, and some of their caregivers, who will be randomly assigned to receive either …

This study aims to understand how children's bodies process a liquid form of the cancer drug venetoclax, which is made by crushing tablets. It involves 30 children and young adults with blood cancers who cannot swallow pills and are already receiving this liquid medicine as part …